Marcel F. Jonkman

Marcel F. Jonkman

Auto-generated profile, based on publicly available information

Marcel F. Jonkman

University of Groningen, University Medical Center Groningen, Department of Dermatology, Center for Blistering Diseases, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RCRaymond J. Cho
Raymond J. Cho
LALudmil B. Alexandrov
Ludmil B. Alexandrov
NBNicoline Y. Den Breems
Nicoline Y. Den Breems
VAVelina S. Atanasova
Velina S. Atanasova
MFMehdi Farshchian
Mehdi Farshchian
ASAndrew P. South
Andrew P. South
Early-onset squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients is characterized by APOBEC mutagenesis.

1 February 2019 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
JMJoost M. Meijer
Joost M. Meijer
GDGilles F. H. Diercks
Gilles F. H. Diercks
ELEmma W. G. de Lang
Emma W. G. de Lang
HPHendri H. Pas
Hendri H. Pas
MJMarcel F. Jonkman
Marcel F. Jonkman
More than 20% of patients with bullous pemphigoid do not present with typical skin blistering, but with a pruritic nonbullous variant consisting of erythematous urticarial plaques, eczematous lesions, papules and nodules, or only excoriations.1-3 These patients with nonbullous pemphigoid may often have a misdiagnosis or be overlooked with a prolonged physician delay, especially in cases in which blisters never develop.3,4 Bullous pemphigoid is the most frequent subepidermal autoimmune bullous disease (sAIBD) and mainly affects older people.1,5 It is characterized by the presence of circulating IgG autoantibodies targeting the structural proteins BP180 and BP230 of the epidermal basement membrane zone.5 Annual incidence of bullous pemphigoid in Europe has increased substantially in the past decades, which might be attributed to an aging population, the availability of better diagnostic tests, and the recognition of patients with atypical clinical features.1,6

1 May 2018 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
ALAniek Lamberts
Aniek Lamberts
JMJoost M. Meijer
Joost M. Meijer
MJMarcel F. Jonkman
Marcel F. Jonkman

23 October 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
RBR. Baardman
R. Baardman
VYV.K. Yenamandra
V.K. Yenamandra
JDJ.C. Duipmans
J.C. Duipmans
APAnna Pasmooij
Anna Pasmooij
MJM.F. Jonkman
M.F. Jonkman
MBM.C. Bolling
M.C. Bolling
Background: Epidermolysis bullosa (EB) is a heterogeneous group of rare and incurable genetic disorders characterized by fragility of the skin and mucosae, resulting in blisters and erosions. Several epidemiological studies in other populations have been carried out, reporting varying and sometimes inconclusive figures, highlighting the need for standardized epidemiological analyses in well‐characterized cohorts.Objectives: To evaluate the epidemiological data on EB in the Netherlands, extracted from the molecularly well‐characterized cohort in the Dutch EB Registry.Methods: In this observational study all EB‐patients that were based in the Netherlands and captured in the Dutch EB Registry between 1988 and 2018 were included. The epidemiological outcomes were based on complete diagnostic data (clinical features, immunofluorescence, electron microscopy and mutation analysis), with longitudinal follow‐up.Results: A total of 464 EB‐patients (287 families) were included. The incidence and point‐prevalence of EB in the Netherlands were 41.3 per million live births and 22.4 per million population, respectively. EB Simplex (EBS), Junctional EB (JEB), Dystrophic EB (DEB) and Kindler EB were diagnosed in 45.7%, 18.8%, 34.7% and 0.9% of the EB‐patients, respectively, with an incidence and point‐prevalence of 17.5 and 11.9 (EBS), 9.3 and 2.1 (JEB), 14.1 and 8.3 (DEB), 0.5 and 0.2 (Kindler EB). In 90.5% of the EB‐patients the diagnosis was genetically confirmed. During the investigated time period 73 EB‐patients died, 72.6% of whom as a direct consequence of their EB.Conclusion: The epidemiological outcomes of EB in the Netherlands are high, attributed to a high detection rate in a well‐organized set‐up, indicating that EB might be more common than previously assumed. These epidemiological data help to understand the extensive need for (specialized) medical care of EB‐patients and is invaluable for the design and execution of therapeutic trials. This study emphasizes the importance of thorough reporting systems and registries worldwide.

1 April 2018 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
JMJoost M. Meijer
Joost M. Meijer
IAIngeborg Atefi
Ingeborg Atefi
GDGilles F.H. Diercks
Gilles F.H. Diercks
AVArtem Vorobyev
Artem Vorobyev
JZJanny Zuiderveen
Janny Zuiderveen
MJMarcel F. Jonkman
Marcel F. Jonkman

24 February 2015 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
KGKatarzyna B. Gostyńska
Katarzyna B. Gostyńska
MNMiranda Nijenhuis
Miranda Nijenhuis
HLHenny Lemmink
Henny Lemmink
HPHendri H. Pas
Hendri H. Pas
APAnna M.G. Pasmooij
Anna M.G. Pasmooij
MJMarcel F. Jonkman
Marcel F. Jonkman
PLEC, the gene encoding the cytolinker protein plectin, has eight tissue-specific isoforms in humans, arising by alternate splicing of the first exon. To date, all PLEC mutations that cause epidermolysis bullosa simplex (EBS) were found in exons common to all isoforms. Due to the ubiquitous presence of plectin in mammalian tissues, EBS from recessive plectin mutations is always associated with extracutaneous involvement including muscular dystrophy, pyloric atresia and cardiomyopathy. We studied a consanguineous family with sisters having isolated blistering suggesting EBS. Skin disease started with foot blisters at walking age and became generalized at puberty while sparing mucous membranes. DNA sequencing revealed a homozygous nonsense mutation (c.46C>T; p.Arg16X) in the first exon of the plectin variant encoding plectin isoform 1a (P1a). Immunofluorescence antigen mapping, transmission electron microscopy, western blot analysis and qRT-PCR were performed on patient skin and cultured keratinocytes, control myocardium and striated muscle samples. We found hypoplastic hemidesmosomes and intra-epidermal ‘pseudo-junctional’ cleavage fitting EBS. Screening for cardiomyopathy and muscle dystrophy showed no abnormalities. We report the first cases of autosomal-recessive EBS from P1a deficiency affecting skin, while mucous membranes, heart and muscle are spared. The dominant expression of the P1a isoform in epidermal basal cell layer and cultured keratinocytes suggests that mutations in the first exon of isoform 1a cause skin-only EBS without extracutaneous involvement. Our study characterizes yet another of the eight isoforms of plectin and adds a tissue-specific phenotype to the spectrum of ‘plectinopathies' produced by mutations of unique first exons of this gene.